+

WO2011093812A3 - Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche - Google Patents

Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche Download PDF

Info

Publication number
WO2011093812A3
WO2011093812A3 PCT/TR2011/000014 TR2011000014W WO2011093812A3 WO 2011093812 A3 WO2011093812 A3 WO 2011093812A3 TR 2011000014 W TR2011000014 W TR 2011000014W WO 2011093812 A3 WO2011093812 A3 WO 2011093812A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
budesonide
dry powder
powder form
pharmaceutical formulation
Prior art date
Application number
PCT/TR2011/000014
Other languages
English (en)
Other versions
WO2011093812A2 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00621A external-priority patent/TR201000621A2/xx
Priority claimed from TR2010/00732A external-priority patent/TR201000732A2/xx
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093812A2 publication Critical patent/WO2011093812A2/fr
Publication of WO2011093812A3 publication Critical patent/WO2011093812A3/fr
Priority to US13/531,972 priority Critical patent/US8834931B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0233—Conductive materials, e.g. antistatic coatings for spark prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/19—Constructional features of carpules, syringes or blisters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques sous forme de poudre sèche comprenant du tiotropium et du budésonide et/ou leurs dérivés pharmaceutiquement acceptables utilisés comme principes actifs. Elle concerne également des formes en capsules ou plaquettes alvéolaires contenant ces compositions pharmaceutiques destinées à être utilisées dans le traitement de maladies des voies respiratoires.
PCT/TR2011/000014 2009-12-25 2011-01-28 Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche WO2011093812A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00621A TR201000621A2 (tr) 2010-01-28 2010-01-28 Tiotropium ve budesonid içeren kuru toz formundaki farmasötik kompozisyon
TR2010/00621 2010-01-28
TR2010/00732 2010-02-02
TR2010/00732A TR201000732A2 (tr) 2010-02-02 2010-02-02 Tiotropyum ve budesonid içeren kuru toz formundaki farmasötik kompozisyon

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000015 Continuation-In-Part WO2011093813A1 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique de poudre sèche comprenant le tiotropium et le fluticasone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000012 Continuation-In-Part WO2011093810A2 (fr) 2009-12-25 2011-01-28 Composition pharmaceutique de poudre sèche comprenant du tiotropium et de la mométasone

Publications (2)

Publication Number Publication Date
WO2011093812A2 WO2011093812A2 (fr) 2011-08-04
WO2011093812A3 true WO2011093812A3 (fr) 2012-02-02

Family

ID=44065663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000014 WO2011093812A2 (fr) 2009-12-25 2011-01-28 Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche

Country Status (1)

Country Link
WO (1) WO2011093812A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109210A1 (fr) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations en poudre sèche comprenant du budésonide
WO2013109220A1 (fr) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations en poudre sèche comprenant du tiotropium, du formotérol et du budésonide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053648A1 (fr) * 2003-12-03 2005-06-16 Microdrug Ag Poudre seche predosee a inhaler pour medicaments hydrosensibles
WO2008102128A2 (fr) * 2007-02-19 2008-08-28 Cipla Limited Combinaisons pharmaceutiques
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
WO2011093817A1 (fr) * 2010-01-29 2011-08-04 Mahmut Bilgic Compositions pharmaceutiques comprenant du tiotropium, du formotérol et du budésonide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE378109B (fr) 1972-05-19 1975-08-18 Bofors Ab
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
WO2005053648A1 (fr) * 2003-12-03 2005-06-16 Microdrug Ag Poudre seche predosee a inhaler pour medicaments hydrosensibles
WO2008102128A2 (fr) * 2007-02-19 2008-08-28 Cipla Limited Combinaisons pharmaceutiques
WO2011093817A1 (fr) * 2010-01-29 2011-08-04 Mahmut Bilgic Compositions pharmaceutiques comprenant du tiotropium, du formotérol et du budésonide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KEAT THENG CHOW ET AL: "Investigation of Electrostatic Behavior of a Lactose Carrier for Dry Powder Inhalers", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 25, no. 12, 26 June 2008 (2008-06-26), pages 2822 - 2834, XP019647910, ISSN: 1573-904X, DOI: 10.1007/S11095-008-9651-Y *

Also Published As

Publication number Publication date
WO2011093812A2 (fr) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2012016889A3 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
IL216741A (en) History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2013183062A3 (fr) Formulations d'ibuprofène de goût agréable
WO2014016548A3 (fr) Composition pharmaceutique
WO2012098562A3 (fr) Compositions liquides pour administration par voie orale de sels de lanthane
WO2013114371A8 (fr) Formulation en poudre sèche de dnase i
TR201000681A2 (tr) İnhalasyon yoluyla alınan kuru toz formülasyonları.
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
WO2011093815A3 (fr) Compositions pharmaceutiques comprenant du formotérol et du mométasone
WO2011093818A3 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
WO2011101734A3 (fr) Poudre à goût masqué pour compositions en suspension de méthylprednisolone
WO2011093811A3 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
WO2011139249A3 (fr) Composition pharmaceutique renfermant du cefdinir
WO2011093812A3 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
WO2011093814A3 (fr) Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
WO2012030308A3 (fr) Formulation comprenant la cellobiose
WO2011037549A3 (fr) Formulation de poudre sèche de tiotropium contenue dans une bande alvéolée thermoformée
EP2583966A4 (fr) Dérivé de rgd cyclique marqué par du tricarbonyl-technétium-99m ou -rhénium-188, son procédé de préparation et composition pharmaceutique contenant le dérivé comme principe actif destinée à être utilisée dans le diagnostic ou le traitement de maladies liées à l'angiogenèse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11710053

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11710053

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载